Shanghai Haohai Biological to Stage $305 Million IPO in Hong Kong

Shanghai Haohai Biological Technology, a company that makes medical products from absorbable biomedical materials, announced plans to raise as much as $305 million in an IPO on the Hong Kong Stock Exchange. The company will use 25% of the proceeds to update its production facilities and another 25% for acquisitions of other biomedical material companies. The company has a portfolio of 14 biomedical products, three of which are drugs and the rest Class III medical devices. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.